Table 3

Baseline mean scores (SD) by treatment arm
EORTC-QLQ C30 CR TT
(n=62) (n=59)
physical functioning 84,1 (18,7) 83,2 (16,0)
role functioning 70,2 (27,4) 66,4 (29,3)
cognitive functioning 86,0 (20,5) 82,8 (22,3)
emotional functioning 78,8 (18,1) 74,4 (20,0)
social functioning 80,6 (22,6) 82,2 (19,8)
fatigue 29,7 (20,7) 35,0 (24,9)
nausea & vomiting 7,5 (19,0) 5,1 (15,2)
pain 24,7 (24,7) 24,5 (24,4)
global health status 69,0 (21,7) 67,2 (17,5)
dyspnea 11,3 (22,5) 15,3 (26,5)
insomnia 26,9 (28,2) 35,0 (29,3)
loss of appetite 12,9 (27,2) 10,2 (18,8)
obstipation 12,4 (25,8) 11,3 (18,2)
diarrhea 6,5 (16,9) 4,0 (12,5)
financial difficulty 9,7 (24,4) 13,0 (24,8)
EORTC-QLQ BR23 CR TT
(n=62) (n=59)
systemic treatment side effects 13,9 (14,2) 15,4 (16,0)
body image 73,7 (28,6) 73,0 (30,9)
future perspective 52,7 (29,9) 54,2 (29,0)
arm symptoms 23,8 (22,6) 24,9 (21,6)
breast symptoms 21,9 (18,6) 19,9 (16,6)
CR (n=8) TT (n=13)
upset by hair loss 33,3 (35,6) 35,9 (39,6)
CR (n=56) TT (n=54)
sexual functioning 22,3 (23,2 25,0 (23,3)
CR (n=28) TT (n=33)
sexual enjoyment 56,0 (28,8) 55,6 (28,5)

Versmessen et al.

Versmessen et al. BMC Cancer 2012 12:495   doi:10.1186/1471-2407-12-495

Open Data